ARS Pharma has claimed FDA approval for its epinephrine nasal spray neffy, becoming the first ... associate director of the division of pulmonology, allergy and critical care at the FDA's Center ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute repetitive seizures, also referred to as seizure clusters ...

Satsuma, a unit of a Japanese drugmaker with U.S. headquarters in Durham, said its treatment, called Atzumi, received its new ...

The US Food and Drug Administration (FDA) has approved dihydroergotamine (DHE) nasal powder (Atzumi, Satsuma Pharmaceuticals Inc) for the acute treatment of migraine with or without aura in adults ...

The FDA just approved a new nasal application for allergy medicine. Pennsylvania law allows for school nurses to train other ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

In this younger patient population, diazepam nasal spray was readily absorbed and demonstrated a consistent PK profile with that of older children and adults aged 6 to 59 years. The Food and Drug ...

ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray ... 15 and 30kg. Approved by the US Food and Drug Administration (FDA) in March 2025, the spray is now ...

The FDA approved dihydroergotamine ... DHE is a migraine-specific acute medication first approved in 1946. It comes in several forms, including nasal sprays, injection, intravenous infusion ...